Biotype markers to guide care for early psychosis
5/5 - Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
The team uses brainwave, eye movement, and thinking tests to sort young people with early psychosis into groups that may predict their recovery path.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11141077 on NIH RePORTER |
What this research studies
You would be followed after the first episode of psychosis at coordinated specialty care clinics across five sites. Researchers will collect EEG brainwave recordings, eye-movement tests, neurocognitive testing, and clinical and demographic information. They will place participants into previously validated "Biotypes" and track symptoms, functioning, and treatment response at 1, 6, and 12 months. The goal is to see whether these biomarker-based groups match different recovery trajectories in early-course psychosis.
Who could benefit from this research
Good fit: Ideal candidates are people roughly 18–35 years old experiencing early-course psychosis (including bipolar disorder with psychosis, schizophrenia, or schizoaffective disorder) and receiving care at participating coordinated specialty clinics.
Not a fit: People who do not have psychotic symptoms, are far beyond the early stage of illness, or cannot complete EEG or eye-movement testing are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, this could help doctors personalize treatment early by identifying who is likely to recover and who may need more intensive care.
How similar studies have performed: Earlier B-SNIP work replicated and validated these EEG/eye-movement/cognition "Biotypes" in larger samples, though applying them specifically to early-course psychosis is a newer step.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Clementz, Brett a — University of Georgia
- Study coordinator: Clementz, Brett a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.